Detection of novel drug-adverse drug reaction signals in rheumatoid arthritis and ankylosing spondylitis: analysis of Korean real-world biologics registry data
Open Access
- 1 February 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Abstract
This study aimed to detect signals of adverse drug reactions (ADRs) associated with biological disease-modifying antirheumatic drugs (DMARDs) and targeted therapies in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients. Utilizing the KOrean College of Rheumatology BIOlogics & Targeted Therapy Registry (KOBIO) data, we calculated relative risks, excluded previously reported drug-ADR pairs, and externally validated remaining pairs using US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and single centre’s electronic health records (EHR) data. Analyzing data from 2279 RA and 1940 AS patients, we identified 35 significant drug-ADR pairs in RA and 26 in AS, previously unreported in drug labels. Among the novel drug-ADR pairs from KOBIO, 15 were also significant in the FAERS data. Additionally, 2 significant drug-laboratory abnormality pairs were found in RA using CDM MetaLAB analysis. Our findings contribute to the identification of 14 novel drug-ADR signals, expanding our understanding of potential adverse effects related to biological DMARDs and targeted therapies in RA and AS. These results emphasize the importance of ongoing pharmacovigilance for patient safety and optimal therapeutic interventions.Keywords
Funding Information
- Konyang University Myung-gok Research Fund (20-06)
- National Research Foundation of Korea (2021R1I1A3044287)
This publication has 29 references indexed in Scilit:
- A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug ReactionsDrug Safety, 2015
- Active-comparator design and new-user design in observational studiesNature Reviews Rheumatology, 2015
- Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactionsJournal of the American Medical Informatics Association, 2012
- The U.S. Food and Drug Administration's Mini‐Sentinel program: status and directionPharmacoepidemiology and Drug Safety, 2012
- Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes PartnershipAnnals of Internal Medicine, 2010
- The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in FrancePharmacoepidemiology and Drug Safety, 2006
- An Assessment of the Publicly Disseminated Evidence of Safety Used in Decisions to Withdraw Medicinal Products from the UK and US MarketsDrug Safety, 2006
- Quantitative Methods in PharmacovigilanceDrug Safety, 2003
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001
- Principles of Signal Detection in PharmacovigilanceDrug Safety, 1997